The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands Mounjaro and Zepbound, in India by 2025. The proposed dosages ranged from 2.5 mg to 15 mg.

The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s (LLY) popular diabetes and weight-loss drugs Mounjaro and Zepbound — is officially over.

The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” In addition to the GLP-1 prescription, the FDA suggests that users reduce their calorie intake and increase their exercise.

In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.